Cyclosporin for severe childhood atopic dermatitis: Short course versus continuous therapy

British Journal of Dermatology

Volumn 142, Issue 1, 2000, Pages 52-58

  Harper, J I ^a   Ahmed, I ^b   Barclay, G ^b   Lacour, M ^a   Hoeger, P ^a   Cork, M J ^c   Finlay, A Y ^d   Wilson, N J E ^e   Graham Brown, R A C ^f   Sowden, J M ^g   Beard, A L ^h   Sumner, M J ^h   Berth Jones, J ^b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b WALSGRAVE HOSPITAL   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^f LEICESTER ROYAL INFIRMARY   (United Kingdom)

^g WREXHAM MAELOR HOSPITAL   (United Kingdom)

^h Novartis Pharmaceuticals UK Ltd   (United Kingdom)

Author keywords

Atopic dermatitis; Childhood; Cyclosporin; Rule of Nines; SASSAD; Short course therapy

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLICULITIS; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERTRICHOSIS; MALE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; RHINITIS; STEROID THERAPY; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME;

EID: 0033959268     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03241.x     Document Type: Article

References (10)

1. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-9.
2. Long CC, Funnell CM, Collard R et al. What do members of the National Eczema Society really want? Clin Exp Dermatol 1993; 18: 516-22.
3. Finlay AY. Measures of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol 1996; 7: 149-54.
4. Reynolds NJ. Recent advances in atopic dermatitis. J R Coll Phys London 1997; 31: 241-5.
5. Harper J. Traditional Chinese medicine for eczema. Br Med J 1994; 308: 489-90.
6. Salek MS, Finlay AY, Luscombe DK et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis: a randomized, double blind, placebo-controlled trial. Br J Dermatol 1993; 129: 422-30.
7. Berth-Jones J, Graham-Brown RAC, Marks R et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997; 136: 76-81.
8. Berth-Jones J, Finlay AY, Zaki I et al. Cyclosporin in severe childhood atopic dermatitis. A multicentre study. J Am Acad Dermatol 1996; 34: 1016-21.
9. Berth-Jones J. Six Area Six Sign AD (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996; 135 (Suppl. 48): 25-30.
10. Sowden JM, Berth-Jones J, Ross JS et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338: 137-40.